University Home | Hospital | Pulse Employment | Contact Us | Search | News 
Thomas Jefferson University Search Jefferson
Jefferson Medical College Jefferson College of Graduate Studies Jefferson College of Health Professions
Menu
Thomas Jefferson University - Matthias J. Schnell, PhD
Matthias J. Schnell, PhD

Microbiology & Immunology
Thomas Jefferson University
Jefferson Medical College
Department of Microbiology and Immunology
Professor
Director, Jefferson Vaccine Center
Mailing Address
233 South 10th St., 531 BLSB
Philadelphia, Pennsylvania 19107-5541
United States
Contact Information
Phone: 215-503-4634
Fax: 215-503-5393
Matthias.Schnell@jefferson.edu
Qualifications
B.S., M.S., Ph.D., University of Stuttgart-Hohenheim & Federal Research Center for Virus Diseases of Animals; Tuebingen, Germany, 1994
Expertise and Research Interests
Research interest:
The research interest of the laboratory is focus on two areas: 1) viral pathogenesis and 2) vaccine development
Viral pathogenicity: We are interested in a detailed understanding of the biochemistry, molecular biology and immunology of rabies virus and its interaction with the infected host. The molecular mechanism of rabies virus pathogenesis is not well understood and our research analyses the different functions the rhabdoviral proteins (e.g. rabies virus) and their interaction with cellular host proteins. Current projects are directed to:
* RV virus neurotropism and neuroinvasiveness
* The cellular RV receptor(s) for pathogenic and attenuated RV strains, RV entry into cells.
* Immune responses of RV in the infected host (innate and adaptive)
Vaccines: The other focus of the laboratory are Rhabdovirus-based vectors as vaccines against other infectious diseases.
* Using different molecular approaches, we perform detailed studies of highly attenuated RV expressing HIV-1 or filovirus (e.g Ebola/Marburg) genes and analyze their immunogenicity in mice. The most promising HIV and Ebola virus vaccine candidates are currently under investigation to prevent disease in monkey models.
* Novel vaccines against filoviruses  Currently we study the efficacy of this novel, rabies virus based vaccine platform in NHP.
" New approaches using genetically modified RV G proteins carrying antigens of other pathogens are developed as novel vaccines against Anthrax and Botulism.
" Development of safer and more potent vaccines for wildlife and human rabies.
Other Expertise
Editorial Positions:

2000 -2005 Editorial Board, Journal of General Virology
2003 -present Editorial Board, Journal of Virology
2005-present Editorial Board, Journal of Bioterrorism & Biodefense
2009-present HIV/AIDS - Research and Palliative Care
2010-present Guest Editor, PLOS Pathogens
2012-present Editorial Board, Virus Research
2012-present Editorial Board, Journal of Vaccines
2012-present Academic Editor, PLOS One
NIH Study Sections and grant reviews
* Different NIH/NIAID Special Emphasis for HIV vaccines, Molecular and Experimental Virology, Virology and Biodefense (2002-present)
* Member, Microbiology and Infectious Diseases Research Committee of the NIAID (2006-2008)
* Review and Site visit of the Oregon National Primate Research Center (ONPRC) 2008
* Ad hoc member VIRA study section (2009-present)
* Chair, RFA-NIH-NIAID-AI-11025 Special Emphasis Panel Therapeutics for Neurotropic Biodefense Toxins and Pathogens 2012

Others:
* U.S. Civilian Research and Development Foundation (CRDF)
* Fonds zur Förderung der wissenschaftlichen Forschung (FWF), Austrian Science Fund
* AIDS Fonds, The Netherlands
The Netherlands Organisation for Health Research and Development
* German Research Foundation (DFG)
* DOD - Basic and Applied Sciences Directorate Defense Threat Reduction Agency (DTRA)
* U.S. Army Corps of Engineers Engineer Research and Development Centers (ERDC)
* Medical Research Council (UK)
* Defense Threat Reduction Agency (US army)


Industrial Relevance
Design of novel vaccines against infectious diseases (HIV-1, Ebola, Anthrax, Botulinum neurotoxin, and other infectious diseases)
Keywords
microbiology; biochemistry; immunology; molecular virology; vaccines; negative strand RNA viruses; rhabdoviruses; rabies virus; vesicular stomatitis virus; biodefense; HIV; SARS-CoV; anthrax; botulinum neurotoxin; neurovirology; neurotropic viruses; pathogenesis
Languages
English, German
Publications
  • 1. Gomme EA, Wirblich C, Addya S, Rall GF, Schnell MJ. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression. PLoS pathogens. 2012;8(10):e1002971. PMCID: 3469654
  • 2. Marston DA, McElhinney LM, Banyard AC, Horton DL, Nunez A, Koser ML, Schnell MJ, Fooks AR. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein. The Journal of general virology. 2012. PMCID:
  • 3. Nguyen TD, Wirblich C, Aizenman E, Schnell MJ, Strick PL, Kandler K. Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing. J Neurosci Methods. 2012;209(2):367-70. PMCID: 3429795
  • 4. Nunnari G, Coco C, Pinzone MR, Pavone P, Berretta M, Di Rosa M, Schnell MJ, Calabrese G, Cacopardo B. The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed). 2012;4:2442-56. PMCID:
  • 5. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology. 2012;434(1):18-26. PMCID: 3484205
  • 6. Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine. 2012;30(43):6136-41. PMCID: 3434297
  • 7. Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012;426(2):120-33. PMCID: 3294073
  • 8. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. Journal of virology. 2011;85(20):10605-16. PMCID: 3187516
  • 9. Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ. Rabies virus as a research tool and viral vaccine vector. Advances in virus research. 2011;79:139-64. PMCID:
  • 10. Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine. 2011;29(28):4638-45. PMCID: 3114282
  • 11. Nunnari G, Schnell MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed). 2011;3:1032-7. PMCID:
  • 12. Wirblich C, Schnell MJ. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. Journal of virology. 2011;85(2):697-704. PMCID: 3020019
  • 13. Faul EJ, Wanjalla CN, Suthar MS, Gale M, Wirblich C, Schnell MJ. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling. PLoS pathogens. 2010;6(7):e1001016. PMCID: 2908622
  • 14. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. Journal of virology. 2010;84(6):2820-31. PMCID: 2826042
  • 15. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. Journal of virology. 2010;84(16):8300-7. PMCID: 2916528
  • 16. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y. A novel composite immunotoxin that suppresses rabies virus production by the infected cells. Journal of immunological methods. 2010;353(1-2):78-86. PMCID: 2823984
  • 17. Prehaud C, Wolff N, Terrien E, Lafage M, Megret F, Babault N, Cordier F, Tan GS, Maitrepierre E, Menager P, Chopy D, Hoos S, England P, Delepierre M, Schnell MJ, Buc H, Lafon M. Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. Science signaling. 2010;3(105):ra5. PMCID:
  • 18. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nature reviews Microbiology. 2010;8(1):51-61. PMCID:
  • 19. Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine. 2010;29(1):130-40. PMCID: 2997164
  • 20. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. The Journal of infectious diseases. 2009;200(8):1251-60. PMCID:
  • 21. Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine. 2009;28(2):299-308. PMCID: 2826816
  • 22. Faul EJ, Lyles DS, Schnell MJ. Interferon response and viral evasion by members of the family rhabdoviridae. Viruses. 2009;1(3):832-51. PMCID: 3185512
  • 23. Preuss MA, Faber ML, Tan GS, Bette M, Dietzschold B, Weihe E, Schnell MJ. Intravenous inoculation of a bat-associated rabies virus causes lethal encephalopathy in mice through invasion of the brain via neurosecretory hypothalamic fibers. PLoS pathogens. 2009;5(6):e1000485. PMCID: 2691950
  • 24. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer research. 2009;69(8):3537-44. PMCID: 2707278
  • 25. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine. 2008;26(50):6405-14. PMCID: 2629409
  • 26. Dietzschold B, Li J, Faber M, Schnell M. Concepts in the pathogenesis of rabies. Future virology. 2008;3(5):481-90. PMCID: 2600441
  • 27. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008;382(2):226-38. PMCID: 2645003
  • 28. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine. 2008;26(3):419-26. PMCID: 2185713
  • 29. Pulmanausahakul R, Li J, Schnell MJ, Dietzschold B. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. Journal of virology. 2008;82(5):2330-8. PMCID: 2258906
  • 30. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. Journal of the National Cancer Institute. 2008;100(13):950-61. PMCID: 2749952
  • 31. Weihe E, Bette M, Preuss MA, Faber M, Schafer MK, Rehnelt J, Schnell MJ, Dietzschold B. Role of virus-induced neuropeptides in the brain in the pathogenesis of rabies. Developments in biologicals. 2008;131:73-81. PMCID:
  • 32. Wirblich C, Tan GS, Papaneri A, Godlewski PJ, Orenstein JM, Harty RN, Schnell MJ. PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity. Journal of virology. 2008;82(19):9730-8. PMCID: 2546990
  • 33. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. Journal of virology. 2007;81(13):7041-7. PMCID: 1933278
  • 34. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. The Journal of infectious diseases. 2007;195(7):980-8. PMCID:
  • 35. Tan GS, Preuss MA, Williams JC, Schnell MJ. The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(17):7229-34. PMCID: 1855364
  • 36. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006;348(2):489-97. PMCID:
  • 37. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006;356(1-2):147-54. PMCID:
  • 38. McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 2006;344(2):363-77. PMCID:
  • 39. Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC. Immunogenicity of cytopathic and noncytopathic viral vectors. Journal of virology. 2006;80(13):6259-66. PMCID: 1488949
  • 40. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006;353(2):344-56. PMCID: 1576297
  • 41. Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. Journal of virology. 2006;80(20):10010-20. PMCID: 1617304
  • 42. Tang J, Olive M, Pulmanausahakul R, Schnell M, Flomenberg N, Eisenlohr L, Flomenberg P. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology. 2006;350(2):312-22. PMCID:
  • 43. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies. Current topics in microbiology and immunology. 2005;292:45-56. PMCID:
  • 44. Faber M, Bette M, Preuss MA, Pulmanausahakul R, Rehnelt J, Schnell MJ, Dietzschold B, Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. Journal of virology. 2005;79(24):15405-16. PMCID: 1316002
  • 45. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, Dietzschold B, Schnell MJ. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. Journal of virology. 2005;79(22):14141-8. PMCID: 1280225
  • 46. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. The Journal of general virology. 2005;86(Pt 5):1435-40. PMCID: 1361274
  • 47. Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. Journal of neurovirology. 2005;11(1):76-81. PMCID:
  • 48. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005;331(1):82-93. PMCID:
  • 49. Dietzschold ML, Faber M, Mattis JA, Pak KY, Schnell MJ, Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine. 2004;23(4):518-24. PMCID:
  • 50. Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(46):16328-32. PMCID: 528969
  • 51. Goodrich A, Parveen Z, Dornburg R, Schnell MJ, Pomerantz RJ. Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. Molecular therapy : the journal of the American Society of Gene Therapy. 2004;9(4):557-65. PMCID:
  • 52. Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. Journal of virology. 2004;78(6):2657-65. PMCID: 353768
  • 53. Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ. Rabies virus nucleoprotein as a carrier for foreign antigens. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(25):9405-10. PMCID: 438989
  • 54. McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. Journal of virology. 2004;78(24):13455-9. PMCID: 533936
  • 55. Dietzschold B, Faber M, Schnell MJ. New approaches to the prevention and eradication of rabies. Expert review of vaccines. 2003;2(3):399-406. PMCID:
  • 56. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. Journal of virology. 2003;77(20):10889-99. PMCID: 224996
  • 57. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. Journal of virology. 2003;77(1):237-44. PMCID: 140592
  • 58. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Current HIV research. 2003;1(2):229-37. PMCID:
  • 59. McKenna PM, Pomerantz RJ, Dietzschold B, McGettigan JP, Schnell MJ. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. Journal of virology. 2003;77(23):12782-94. PMCID: 262580
  • 60. Parveen Z, Mukhtar M, Rafi M, Wenger DA, Siddiqui KM, Siler CA, Dietzschold B, Pomerantz RJ, Schnell MJ, Dornburg R. Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. Virology. 2003;314(1):74-83. PMCID:
  • 61. Schnell M, Gwinner G, Badnell NR, Bannister ME, Bohm S, Colgan J, Kieslich S, Loch SD, Mitnik D, Muller A, Pindzola MS, Schippers S, Schwalm D, Shi W, Wolf A, Zhou SG. Observation of trielectronic recombination in Be-like Cl ions. Physical review letters. 2003;91(4):043001. PMCID:
  • 62. Dietzschold B, Schnell MJ. New approaches to the development of live attenuated rabies vaccines. Hybridoma and hybridomics. 2002;21(2):129-34. PMCID:
  • 63. Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. Journal of virology. 2002;76(7):3374-81. PMCID: 136034
  • 64. Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. Journal of virology. 2002;76(1):19-31. PMCID: 135731
  • 65. McGettigan JP, McKenna PM, Schnell MJ. HIV-1 vaccines: the search continues. Clinics in laboratory medicine. 2002;22(3):799-820, viii. PMCID:
  • 66. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology. 2002;292(1):24-34. PMCID:
  • 67. Wu X, Gong X, Foley HD, Schnell MJ, Fu ZF. Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated. Journal of virology. 2002;76(9):4153-61. PMCID: 155083
  • 68. Yan X, Mohankumar PS, Dietzschold B, Schnell MJ, Fu ZF. The rabies virus glycoprotein determines the distribution of different rabies virus strains in the brain. Journal of neurovirology. 2002;8(4):345-52. PMCID:
  • 69. Harty RN, Brown ME, Hayes FP, Wright NT, Schnell MJ. Vaccinia virus-free recovery of vesicular stomatitis virus. Journal of molecular microbiology and biotechnology. 2001;3(4):513-7. PMCID:
  • 70. Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. Journal of virology. 2001;75(22):10623-9. PMCID: 114644
  • 71. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, Pomerantz RJ. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001;98(10):3006-15. PMCID:
  • 72. McGettigan JP, Foley HD, Belyakov IM, Berzofsky JA, Pomerantz RJ, Schnell MJ. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. Journal of virology. 2001;75(9):4430-4. PMCID: 114191
  • 73. McGettigan JP, Sarma S, Orenstein JM, Pomerantz RJ, Schnell MJ. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. Journal of virology. 2001;75(18):8724-32. PMCID: 115117
  • 74. Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ. Genetic engineering of live rabies vaccines. Vaccine. 2001;19(25-26):3543-51. PMCID:
  • 75. Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B. High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. Journal of immunological methods. 2001;252(1-2):199-206. PMCID:
  • 76. Pulmanausahakul R, Faber M, Morimoto K, Spitsin S, Weihe E, Hooper DC, Schnell MJ, Dietzschold B. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. Journal of virology. 2001;75(22):10800-7. PMCID: 114661
  • 77. Quinones-Kochs MI, Schnell MJ, Buonocore L, Rose JK. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses. Virology. 2001;287(2):427-35. PMCID:
  • 78. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, Chen SJ, Varnavski AN, LeClair C, Raper SE, Wilson JM. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Molecular therapy : the journal of the American Society of Gene Therapy. 2001;3(5 Pt 1):708-22. PMCID:
  • 79. Schnell MJ. Viral vectors as potential HIV-1 vaccines. FEMS microbiology letters. 2001;200(2):123-9. PMCID:
  • 80. Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(26):14680-5. PMCID: 18978
  • 81. Morimoto K, Foley HD, McGettigan JP, Schnell MJ, Dietzschold B. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. Journal of neurovirology. 2000;6(5):373-81. PMCID:
  • 82. Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(7):3544-9. PMCID: 16276
  • 83. Kahn JS, Schnell MJ, Buonocore L, Rose JK. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 1999;254(1):81-91. PMCID:
  • 84. Chenik M, Schnell M, Conzelmann KK, Blondel D. Mapping the interacting domains between the rabies virus polymerase and phosphoprotein. Journal of virology. 1998;72(3):1925-30. PMCID: 109484
  • 85. Kim SK, Reed DS, Olson S, Schnell MJ, Rose JK, Morton PA, Lefrancois L. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(18):10814-9. PMCID: 27978
  • 86. Schnell MJ, Buonocore L, Boritz E, Ghosh HP, Chernish R, Rose JK. Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. The EMBO journal. 1998;17(5):1289-96. PMCID: 1170477
  • 87. Johnson JE, Schnell MJ, Buonocore L, Rose JK. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. Journal of virology. 1997;71(7):5060-8. PMCID: 191739
  • 88. Kretzschmar E, Buonocore L, Schnell MJ, Rose JK. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. Journal of virology. 1997;71(8):5982-9. PMCID: 191854
  • 89. Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 1997;90(5):849-57. PMCID:
  • 90. Kretzschmar E, Peluso R, Schnell MJ, Whitt MA, Rose JK. Normal replication of vesicular stomatitis virus without C proteins. Virology. 1996;216(2):309-16. PMCID:
  • 91. Mebatsion T, Schnell MJ, Cox JH, Finke S, Conzelmann KK. Highly stable expression of a foreign gene from rabies virus vectors. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(14):7310-4. PMCID: 38980
  • 92. Schnell MJ, Buonocore L, Kretzschmar E, Johnson E, Rose JK. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(21):11359-65. PMCID: 38062
  • 93. Schnell MJ, Buonocore L, Whitt MA, Rose JK. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. Journal of virology. 1996;70(4):2318-23. PMCID: 190073
  • 94. Mebatsion T, Schnell MJ, Conzelmann KK. Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles. Journal of virology. 1995;69(3):1444-51. PMCID: 188731
  • 95. Schnell MJ, Conzelmann KK. Polymerase activity of in vitro mutated rabies virus L protein. Virology. 1995;214(2):522-30. PMCID:
  • 96. Conzelmann KK, Schnell M. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. Journal of virology. 1994;68(2):713-9. PMCID: 236507
  • 97. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. The EMBO journal. 1994;13(18):4195-203. PMCID: 395346
  • 98. Wagner JA, Schnell M, Frank W. [The occurrence of Trichinella in indigenous wildlife]. Berliner und Munchener tierarztliche Wochenschrift. 1988;101(12):413-6. PMCID:

Individual Expertise profile of Matthias J. Schnell, PhD, Copyright © Matthias J. Schnell, PhD.
Last Updated by Matthias Schnell, PhD : Friday, November 30, 2012 9:36:16 AM



 Printable Version

Thomas Jefferson University
Thomas Jefferson University